(K.Schum.) Pierre ex Beille
Pausinystalia johimbe, (Rubiaceae), common name Yohimbe, is a plant species native to western and central Africa (Nigeria, Cabinda, Cameroon, Congo-Brazzaville, Gabon, Equatorial Guinea). Extracts from yohimbe have been used in traditional medicine in West Africa as an aphrodisiac and have been marketed in developed countries as dietary supplements.
The active ingredient in the extract, yohimbine, is a veterinary drug used to stimulate recovery from sedation in certain animals. Although proposed as a potential treatment for erectile dysfunction in humans, there are cautions about its safety or effectiveness. Yohimbine is banned in manufactured human products in numerous countries.
Yohimbe is one of five Pausinystalia evergreen species growing in West and Central Africa in lowland forests. The tree grows about 30m tall, with a straight bole that is rarely larger that 50-60 cm in diameter. The bark is grey to reddish-brown, with longitudinal fissures, easy to peel and bitter-tasting. The inner bark is pinkish and fibrous. The sapwood is yellowish and the heartwood is ochre-yellow; the wood is fine-grained and relatively dense and moderately hard. The leaves grow in groups of three, with short (about 2 cm) stems. The blades are oval-shaped, 11-47 cm long and 5 - 17 cm wide. 
Yohimbe bark and extract are widely used in manufactured dietary supplements. However, the bark and extracts are banned from use in food and dietary supplements in many countries, including Great Britain, Ireland, Belgium, the Netherlands, Australia, New Zealand, Denmark, the Czech Republic, and Canada.
The primary alkaloid in the extract, yohimbine, is a veterinary drug used to reverse sedation in dogs, elk or deer. In addition to yohimbine, yohimbe extract contains other alkaloids with undefined properties, adding to concern about its safety. Among other alkaloids is corynanthine, an alpha-1 adrenergic receptor blocker and raubasine.
- Kew World Checklist of Selected Plant Families, Pausinystalia johimbe
- "Yohimbe: MedlinePlus Supplements". MedlinePlus, US National Institutes of Health. Retrieved 2013-05-26.
- Beille, P. E. (2013). "Scientific Opinion on the evaluation of the safety in use of Yohimbe (Pausinystalia yohimbe)". EFSA Journal 11. doi:10.2903/j.efsa.2013.3302.
- R.b. Jiofack Tafokou. Pausinystalia johimbe. pp 516-519 in Timbers Volume 2; Volume 7 of Plant Resources of Tropical Africa. Eds. Lemmens, R.H.M.J., Louppe, D. & Oteng-Amoako, A.A., G.J.H Grubben. PROTA Foundation, 2012. ISBN 9789290814955
- "21 CFR Sec. 522.2670 Yohimbine". US Food and Drug Administration. 2014.
- Doxey, JC; Lane AC; Roach AG; Virdee NK (Feb 1984). "Comparison of the alpha-adrenoceptor antagonist profiles of idazoxan (RX 781094), yohimbine, rauwolscine and corynanthine.". Naunyn-Schmied Arch Pharmacol 325 (2): 136–144. doi:10.1007/bf00506193. PMID 6144048.